Webcasts











Videos and webcasts available on demand

Follow the evidence to help guide chemotherapy decisions for early breast cancer patients

Dr Richard Simcock, Consultant Clinical Oncologist, Brighton and Sussex University Hospitals NHS Trust, and Dr David Hyams, Medical Director,

Clinical utility of multigene assays in early breast cancer: Predictive tests

A presentation by Professor Christos Markopoulos from the University of Athens in Greece talking about the predictive ability of multigene assay in ...

Initial RxPONDER results in clinical practice: What will change?

Dr. Joan Albanell from the Hospital del Mar, Spain and and Dr. Mark Verrill from the Newcastle on Tyne Hospitals, UK discuss the initial RxPONDER ...

Initial RxPONDER results in clinical practice: What will change?

Prof. Stephen Chia from the University of British Columbia, Canada and Dr. Mark Verrill from the Newcastle on Tyne Hospitals, UK discuss the initial ...

Optimizing outcomes in early-stage breast cancer by tailoring the use of chemotherapy

Watch an expert panel at the 2019 St. Gallen International Breast Cancer Conference discuss evidence on how to guide adjuvant chemotherapy treatment ...

The Oncotype DX Breast Recurrence Score assay in clinical practice

Prof. Maccon Keane from the Saolta University Health care Group at the University Hospital Galway in Ireland discusses the Oncotype DX Breast ...

Landmark RxPONDER Trial results presented at the 2020 SABCS

New data clarifies the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Recurrence Score^® results of 0-25.

LEARN MORE

This webpage is intended to be viewed by UK Healthcare Professionals only and not by members of the public. If you are not a healthcare professional, click here for more information

For Patients

Contact Us

Get in Touch

In the US and certain other jurisdictions, Genomic Health, Oncotype DX, Oncotype IQ, Recurrence Score, Oncotype DX Breast Recurrence Score, Oncotype DX Colon Recurrence Score, Oncotype DX Genomic Prostate Score, and Oncotype DX AR-V7 Nucleus Detect are registered trademarks, and "Making cancer care smarter" and GPS are pending registered trademarks, of Genomic Health, Inc., an Exact Sciences corporation.

Making cancer care smarter.™



Webcasts

Videos and webcasts available on demand

Landmark RxPONDER Trial results presented at the 2020 SABCS

Contact Us

Oncotype DX Breast Recurrence Score

Patients and Carers

Resources